Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
H-STAPPAHGV-OH
3D-Ansicht

Biosynth logo

H-STAPPAHGV-OH

Ref. 3D-PP46486

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 27. Dezember 2024

Produktinformation

Name:
H-STAPPAHGV-OH
Synonyme:
  • NH2-Ser-Thr-Ala-Pro-Pro-Ala-His-Gly-Val-OH
Beschreibung:

Peptide H-STAPPAHGV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-STAPPAHGV-OH include the following: Efficient discovery of immune response targets by cyclical refinement of QSAR models of peptide binding V Brusic , K Bucci, C Schönbach , N Petrovsky - Journal of Molecular , 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1093326300000991 Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. V Apostolopoulos , V Karanikas, JS Haurum - (Baltimore, Md.: 1950 , 1997 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/159/11/5211/30949 Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design V Apostolopoulos , IF McKenzie, IA Wilson - Front Biosci, 2001 - article.imrpress.comhttps://article.imrpress.com/bri/Landmark/articles/pdf/LandmarkA683.pdf Vaccine Development Against Novel Breast Cancer Antigens V Apostolopoulos , I McKenzie - 2002 - apps.dtic.milhttps://apps.dtic.mil/sti/citations/tr/ADA409560 Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules V Apostolopoulos , G Chelvanayagam - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/2/767/31120 Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses V Apostolopoulos , DS Pouniotis, PJ van Maanen - Vaccine, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X06000569 Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses S von Mensdorff-Pouilly, L Kinarsky, K Engelmann - , 2005 - academic.oup.comhttps://academic.oup.com/glycob/article-abstract/15/8/735/637686 Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides S von Mensdorff-Pouilly, E Petrakou - Journal of Cancer, 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(20000601)86:5%3C702::AID-IJC16%3E3.0.CO;2-1 HUMORAL IMMUNE RESPONSES BY IMMUNIZATIONS WITH FULLY SYNTHETIC THREE-COMPONENT CANCER VACCINE CANDIDATES PS Thompson - SYNTHESIS AND IMMUNOTHERAPEUTIC STUDIES - getd.libs.uga.eduhttp://getd.libs.uga.edu/pdfs/thompson_pamela_s_201112_phd.pdf#page=142 MUC1-specific Cytotoxic T Lymphocytes Eradicate Tumors When Adoptively Transferred in Vivo P Mukherjee , AR Ginardi, TL Tinder, CJ Sterner - Clinical cancer , 2001 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/7/3/848s/200197 Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred P Mukherjee , AR Ginardi, CS Madsen - The Journal of , 2000 - journals.aai.orghttps://journals.aai.org/jimmunol/article/165/6/3451/69796 Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles P Kumar , C Boyne, S Brown, A Qureshi, P Thorpe - , 2022 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/imm.13471 A central core structure in an antibody variable domain determines antigen specificity P Jirholt, L Strandberg, B Jansson - Protein , 2001 - academic.oup.comhttps://academic.oup.com/peds/article-abstract/14/1/67/1575510 Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies P Brossart, KS Heinrich, G Stuhler - Blood, The Journal , 1999 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/93/12/4309/260963 Synthesis and immunological evaluation of a multicomponent cancer vaccine candidate containing a long MUC1 glycopeptide NT Supekar , V Lakshminarayanan - , 2018 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cbic.201700424 STUDY ON THE EFFECT OF LINKERS IN MONOGLYCOSYLATED LMUC1-BASED MULTICOMPONENT CANCER VACCINE CANDIDATES. NT Supekar - SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF - getd.libs.uga.eduhttps://getd.libs.uga.edu/pdfs/supekar_nitin_t_201612_phd.pdf#page=141 SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF MONOGLYCOSYLATED FULL-LENGTH MUC1-BASED MULTICOMPONENT CANCER VACCINE NT Supekar - SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF - getd.libs.uga.eduhttp://getd.libs.uga.edu/pdfs/supekar_nitin_t_201612_phd.pdf#page=80 Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. N Domenech , RA Henderson , OJ Finn - Journal of immunology , 1995 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/155/10/4766/29001 Immunogenicity of a tripartite cell penetrating peptide containing a MUC1 variable number of tandem repeat (VNTR) and AT helper epitope N Brooks, J Hsu, S Esparon, D Pouniotis, GA Pietersz - Molecules, 2018 - mdpi.comhttps://www.mdpi.com/1420-3049/23/9/2233 Mucin-type O-glycosylation and its potential use in drug and vaccine development MA Tarp, H Clausen - Biochimica et Biophysica Acta (BBAhttps://www.sciencedirect.com/science/article/pii/S0304416507002164 Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/Kb-transgenic mice LC Heukamp, SH van der Burg - journal of cancer, 2001 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0215(200002)9999:9999%3C::AID-IJC1051%3E3.0.CO;2-Z MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer K Yamamoto, T Ueno, T Kawaoka, S Hazama - Anticancer , 2005 - ar.iiarjournals.orghttps://ar.iiarjournals.org/content/25/5/3575.short CG IOANNIDES, B. FISK, KR JEROME, B. CHESAK, T. IRIMURA JT WHARTON, OJ FINN - Ovarian Cancer 3, 2012 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=mMQkBAAAQBAJ&oi=fnd&pg=PA317&dq=(%22NH2-Ser-Thr-Ala-Pro-Pro-Ala-His-Gly-Val-OH%22+OR+%22H-STAPPAHGV-OH%22+OR+%22STAPPAHGV%22)+AND+peptide&ots=X5M8t6Cp2g&sig=cdKQJyLAlV_P86oWpENGmUqCpXo Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells J Gong, V Apostolopoulos , D Chen, H Chen - , 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2567.2000.00101.x Context of MUC1 epitope: immunogenicity IS Quinlin, JS Burnside, KE Dombrowski - Oncology , 2007 - spandidos-publications.comhttps://www.spandidos-publications.com/or/17/2/453 substrate primary amino acid sequence on the activity of human UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferase. Studies with I Nishimori, NR Johnson, SD Sanderson - Journal of Biological , 1994 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0021925817339819 A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway GA Pietersz, W Li, V Apostolopoulos - Vaccine, 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X0000373X Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells EM Hiltbold , MD Alter, P Ciborowski , OJ Finn - Cellular immunology, 1999 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0008874999915125 MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge D Roulois, M Gregoire - BioMed research , 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1155/2013/871936 Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses CK Tang, KC Sheng, D Pouniotis, S Esparon, HY Son - Vaccine, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X08005744 Ovarian tumour reactive cytotoxic T lymphocytes can recognize peptide determinants on polymorphic epithelial mucins Muc-1 CG Ioannides, B Fisk, KR Jerome , B Chesak, T Irimura - Ovarian Cancer 3, 1995 - Springerhttps://link.springer.com/chapter/10.1007/978-1-4757-0136-4_31 Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. B Agrawal, MJ Krantz, MA Reddish - International , 1998 - academic.oup.comhttps://academic.oup.com/intimm/article-abstract/10/12/1907/744541 MUC1 immunobiology: from discovery to clinical applications AM Vlad , JC Kettel, NM Alajez , CA Carlos - Advances in , 2004 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=Bc8PmpSIaUIC&oi=fnd&pg=PA249&dq=(%22NH2-Ser-Thr-Ala-Pro-Pro-Ala-His-Gly-Val-OH%22+OR+%22H-STAPPAHGV-OH%22+OR+%22STAPPAHGV%22)+AND+peptide&ots=QXOvRS5d5C&sig=2B1-87LX83Vbg5pRG_U4MAnoTAw Bridging innate and adaptive antitumor immunity targeting glycans A Pashov , B Monzavi-Karbassi - BioMed Research , 2010 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1155/2010/354068

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP46486 H-STAPPAHGV-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.